NYSE: STVNStevanato Group Spa Stock
$20.98-0.13 (-0.62%)
Updated Mar 26, 2025
STVN Price
$20.98
Fair Value Price
N/A
Market Cap
$6.35B
52 Week Low
$16.56
52 Week High
$32.98
P/E
46.31x
P/B
4.3x
P/S
5.74x
PEG
2.08x
Dividend Yield
N/A
Revenue
$1.16B
Earnings
$122.69M
Gross Margin
27.4%
Operating Margin
16.62%
Profit Margin
10.7%
Debt to Equity
0.66
Operating Cash Flow
$162M
Beta
0.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
STVN Overview
Stevanato Group S.p.A. provides drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It offers glass containers (under its historic Ompi brand), plastic components for diagnostics and medical devices, contract manufacturing services for drug delivery systems, and inspection, assembly and packaging machines. In support of drug development, the company provides analytical services and tests that study the interaction between containers, drugs, and their integration into delivery systems. Stevanato Group S.p.A. was founded in 1949 and is headquartered in Piombino Dese, Italy.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine STVN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
STVN
Ranked#30 of 43
Ranked#30 of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $49.41 | B | |
| $103.70 | B | |
| $6.04 | B |
Be the first to know about important STVN news, forecast changes, insider trades & much more!
STVN News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how STVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STVN ($20.98) is trading above its intrinsic value of $6.01, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STVN is poor value based on its earnings relative to its share price (46.31x), compared to the US market average (31.65x)
P/E vs Market Valuation
STVN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more STVN due diligence checks available for Premium users.
Valuation
STVN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
46.31x
Industry
41.69x
Market
31.65x
STVN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
STVN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
STVN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.3x
Industry
3.78x
STVN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STVN price to earnings growth (PEG)
For valuing profitable companies with growth potential
STVN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
STVN's financial health
Profit margin
Revenue
$344.4M
Net Income
$50.3M
Profit Margin
14.6%
STVN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
STVN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.4B
Liabilities
$963.0M
Debt to equity
0.66
STVN's short-term assets ($926.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STVN's short-term assets ($926.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STVN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
STVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$45.5M
Investing
-$94.8M
Financing
$69.1M
STVN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STVN vs Medical Stocks
Stevanato Group Spa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.